Bosulif (bosutinib) / Pfizer 
Welcome,         Profile    Billing    Logout  

17 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Bosulif (bosutinib) / Pfizer
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
Ascembl, NCT03106779 / 2016-002461-66: Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Hourglass Jan 2019 - Dec 2019 : Completion of P3 trial
Active, not recruiting
3
233
Europe, Canada, Japan, US, RoW
Asciminib, ABL001, Bosutinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
05/20
12/24
2021-000678-27: A study to compare oral asciminib versus existing TKI medicines in patients with newly diagnosed CML Vizsgálat az orálisan alkalmazott asciminib és tirozin-kináz inhibitor (TKI) között újonnan diagnosztizált krónikus mieloid leukémiában (CML) szenvedő betegeknél

Ongoing
3
402
Europe
Asciminib, Bosulif, Glivec, Tasigna, Sprycel, ABL001, STI571, AMN107, Film-coated tablet, Capsule, hard, Bosulif, Glivec, Tasigna, Sprycel
Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients, CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells., Diseases [C] - Cancer [C04]
 
 
ASC4FIRST, NCT04971226 / 2021-000678-27: A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Asciminib, ABL001
Novartis Pharmaceuticals, Novartis Pharma AG
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
11/23
01/28
POLARIS-2, NCT06423911: Study of Olverembatinib (HQP1351) in Patients With CP-CML

Recruiting
3
285
US
olverembatinib, Bosutinib
Ascentage Pharma Group Inc.
Chronic Myeloid Leukemia, CML, CML, Chronic Phase
12/25
02/26
2016-002216-40: Efficacy, safety and tolerability of a drug called Bosutinib, in eldery patients affected by Chronic Myeloid Leukemia failing front-line treatment with other drugs with similar features. Studio sull'efficacia, sicurezza e tollerabilit¿ di un farmaco denominato Bosutinib in pazienti anziani affetti da Leucemia Mieloide Cronica non responsivi a trattamenti di elezione con altri farmaci con caratteristiche simili.

Not yet recruiting
2
65
Europe
Tablet, BOSULIF - 100 MG - COMPRESSA RIVESTITA CON FILM - USO ORALE - BLISTER (PVC/ACLAR/PVC) - 30 COMPRESSE
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Pfizer, A.I.L Associazione Italiana contro le Leucemie
Chronic Myeloid Leukemia (CML) in Chronic Phase Leucemia Mieloide Cronica (LMC) in Fase Cronica, Chronic Myeloid Leukemia (CML) is a type of cancer starts in certain blood-forming cells of the bone marrow. In CML a genetic change takes place in a early (immature) version of myeloid cells- the cel La leucemia mieloide cronica (LMC) ¿ una forma di cancro che ha origine dalle cellule del midollo osseo che rappresentano i precursori delle cellule del sangue (piastrine, globuli rossi e globuli bian, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2018-001843-29: Trial to investigate if the addition of novel agents in combination with TKI can improve response compared to TKI alone in patients with TKI resistant chronic myeloid leukaemia.

Not yet recruiting
2
102
Europe
Imatinib, Nilotinib, Dasatinib, Bosutinib, Ponatinib, Tazemetostat, EPZ-6438, Film-coated tablet, Capsule, hard
NHS Greater Glasgow and Clyde, University of Glasgow, , Cancer Research UK, Epizyme
Chronic myeloid leukaemia, Chronic myeloid leukaemia, Diseases [C] - Cancer [C04]
 
 
2018-001044-54: A study of effect and safety of a new combination of drugs for chronic myeloid leukemia in chronic phase. Bosutinib is the basis treatment and patients will be randomized to receive or not to receive a long-acting low dose of Ropeginterferon. Satunnaistettu, etenevä KML:n ensilinjan lääkehoitotutkimus: Lääkeaineen tehoa ja turvallisuutta mittaava tutkimus, jossa pieniannoksinen ropeginterferoni lisätään bosutinibihoitoon hiljattain diagnosoitua, kroonisessa vaiheessa olevaa kroonista myelooista meukemiaa sairastavilla potilailla.

Not yet recruiting
2
212
Europe
Pegylated proline-interferon alpha 2b, AOP2014, Tablet, Solution for injection in pre-filled pen, Bosulif
St Olavs Hospital -Trondheim University Hospital, Pfizer Norge AS, AOP Orphan Pharmaceuticals AG
Chronic myeloid leukemia at diagnosis-chronich phase Diagnoosivaiheen krooninen myelooinen leukemia, kroonisessa vaiheessa, Chronic myeloid leukemia, a type of blood cancer Krooninen myelooinen leukemia, verisyöpätyyppi, Diseases [C] - Cancer [C04]
 
 
CAPTUR, NCT03297606: Canadian Profiling and Targeted Agent Utilization Trial

Recruiting
2
720
Canada
Olaparib, Dasatinib, Nivolumab plus Ipilimumab, Axitinib, Bosutinib, Crizotinib, Palbociclib, Sunitinib, Temsirolimus, Erlotinib, Trastuzumab plus Pertuzumab, Vemurafenib plus Cobimetinib, Vismodegib, Tucatinib
Canadian Cancer Trials Group, AstraZeneca, Bristol-Myers Squibb, Hoffmann-La Roche, Pfizer, Seagen Inc.
Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
01/26
01/27
AAML1921, NCT04258943 / 2015-002916-34: Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Active, not recruiting
1/2
60
US
Bosutinib
Children's Oncology Group, Erasmus Medical Center, Dutch Childhood Oncology Group, Innovative Therapies for Children with Cancer, Pfizer
Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia
07/28
07/28
NCT04793399: Safety and Efficacy Evaluation of Bosutinib Plus Atezolizumab in Newly Diagnosed Chronic Leukemia Adult Patients

Terminated
1/2
9
Europe
Bosutinib 400 MG Monotherapy, Bosulif, Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection, Bosulif + Tecentriq
Fundacion Espanola para la Curacion de la Leucemia Mieloide Cronica, Pfizer, Roche Farma, S.A
Chronic Phase-Chronic Myeloid Leukemia
09/21
09/21
NCT04744532: iPSC-based Drug Repurposing for ALS Medicine (iDReAM) Study

Recruiting
1/2
49
Japan
Bosutinib (Phase 1 part), PF-05208763, Bosutinib (Phase 2 part)
Kyoto University, Tokushima University, Kitasato University, Tottori University, Nara Medical University, Toho University, Hiroshima University, Pfizer
Amyotrophic Lateral Sclerosis
03/24
03/24
NCT03854903: WI231696: Bosutinib, Palbocicilib and Fulvestrant for HR+HER2- Advanced Breast Cancer Refractory to a CDK4/6 Inhibitor

Active, not recruiting
1
19
US
Palbociclib, Ibrance, Bosutinib, Bosulif, Fulvestrant, Faslodex
Georgetown University, Pfizer
Metastatic Breast Cancer, Human Epidermal Growth Factor 2 Negative Carcinoma of Breast, Hormone Receptor Positive Breast Cancer
11/23
11/25
NCT02921477: Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias

Enrolling by invitation
1
150
US
bosutinib, bosulif, TKI
Neurological Associates of West Los Angeles, Pfizer
Mild Cognitive Impairment, Dementia
12/23
12/25
NCT05743465: A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

Completed
N/A
1769
US
No Intervention
Takeda
Leukemia
11/22
11/22
BLF, NCT02501330: Safety And Efficacy Of Bosutinib

Completed
N/A
702
Japan
Bosutinib, BOSULIF
Pfizer
Chronic Myelogenous Leukemia
02/24
02/24
NCT06297161: A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

Not yet recruiting
N/A
600
NA
Bosulif
Pfizer
Chronic Leukemia Myelogenous
12/29
12/29

Download Options